PREVAIL Impresses, But Prostate Docs Wary Of Declaring Victory For Xtandi Over Zytiga
Bullish analysts predicted Xtandi easily wins over first-to-market Zytiga in pre-chemo prostate cancer, based on PREVAIL findings. But in the formal presentation at the ASCO GU meeting, clinicians were more reluctant to compare the two drugs and took a more nuanced interpretation of the data, given the important differences in study designs.